136 related articles for article (PubMed ID: 31922700)
21. Health Canada's use of its priority review process for new drugs: a cohort study.
Lexchin J
BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
[TBL] [Abstract][Full Text] [Related]
22. Patentees research and development expenditure in Canada.
Li S; Tomalin A
J Pharm Pharm Sci; 2002; 5(1):5-11. PubMed ID: 12042113
[TBL] [Abstract][Full Text] [Related]
23. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
24. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
Morgan SG; Vogler S; Wagner AK
Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
[TBL] [Abstract][Full Text] [Related]
25. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
[TBL] [Abstract][Full Text] [Related]
26. Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism.
Hammerman A; Greenberg D
Health Policy; 2009 Jan; 89(1):78-83. PubMed ID: 18579253
[TBL] [Abstract][Full Text] [Related]
27. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
[TBL] [Abstract][Full Text] [Related]
28. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
29. "What's up with price controls?" Stakeholders' views on the regulation of pharmaceutical pricing in Malaysia.
Loh YSL; Siah AKL; Koh SGM; Cheong WL; Su TT
PLoS One; 2023; 18(12):e0291031. PubMed ID: 38060579
[TBL] [Abstract][Full Text] [Related]
30. Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review.
Luo Z; Ruan Z; Yao D; Ung COL; Lai Y; Hu H
Front Public Health; 2021; 9():765999. PubMed ID: 34869180
[No Abstract] [Full Text] [Related]
31. Marketing before patenting: implications for price controls in Canada.
Lexchin J
Open Med; 2010; 4(3):e139-42. PubMed ID: 21687333
[TBL] [Abstract][Full Text] [Related]
32. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
Hammerman A; Feder-Bubis P; Greenberg D
Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
[TBL] [Abstract][Full Text] [Related]
33. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.
Orlewska E; Mierzejewski P
Value Health; 2004; 7(1):1-10. PubMed ID: 14720125
[TBL] [Abstract][Full Text] [Related]
34. Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews.
Makady A; van Acker S; Nijmeijer H; de Boer A; Hillege H; Klungel O; Goettsch W
Value Health; 2019 Apr; 22(4):399-407. PubMed ID: 30975390
[TBL] [Abstract][Full Text] [Related]
35. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
Zaric GS; O'brien BJ
Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
[TBL] [Abstract][Full Text] [Related]
36. Consequences of implementing a drug budget for office-based physicians in Germany.
Schöffski O
Pharmacoeconomics; 1996; 10 Suppl 2():37-47. PubMed ID: 10163434
[TBL] [Abstract][Full Text] [Related]
37. [Competition and prices in the Mexican pharmaceutical market].
Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
[TBL] [Abstract][Full Text] [Related]
38. Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country.
Milovanovic DR; Pavlovic R; Folic M; Jankovic SM
Eur J Clin Pharmacol; 2004 May; 60(3):149-53. PubMed ID: 15057496
[TBL] [Abstract][Full Text] [Related]
39. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
40. Decision-making and evidence use during the process of prenatal record review in Canada: a multiphase qualitative study.
Semenic S; Edwards N; Premji S; Olson J; Williams B; Montgomery P
BMC Pregnancy Childbirth; 2015 Mar; 15():78. PubMed ID: 25881034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
